Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Colorectal Cancer

 

Capecitabine and Celecoxib w/wo Radiation Therapy for Colorectal Cancer Patients Previously Treated With Fluorouracil (ADAPT - 7707)
A Phase II Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer

Investigator: Edward Lin, MD;   Conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer;    Status: Recruiting;   Study ID: NCT01729923

TheraSphere® Metastatic Colorectal Carcinoma of the Liver (7627)
A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy

Investigator: William Harris;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01483027

SIR-Sphere + FOLFOX for Liver Metastases from Colorectal Cancer (UW10025)
Randomised Comparative Study Of Folfox6m Plus SIR-Spheres® Microspheres Versus Folfox6m Alone As First Line Treatment In Patients With Nonresectable Liver Metastases From Primary Colorectal Carcinoma

Investigator: Andrew Coveler, MD;   Conditions: Colorectal Cancer, Colorectal Carcinoma, Liver Metastases;    Status: Recruiting;   Study ID: NCT00724503

FOLFIRI + Ramucirumab for Metastatic Colorectal Cancer (UW10034)
A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab (Avastin), Oxaliplatin, and a Fluoropyrimidine

Investigator: Veena Shankaran;   Conditions: Colon Cancer; Gastrointestinal Cancer; Rectal Cancer; Solid Tumors;    Status: Recruiting;   Study ID: NCT01183780

Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery (NSABP P-5)
Statin Polyp Prevention Trial in Patients with Resected Colon Cancer

Investigator: Tanya Wahl, MD;   Conditions: Colon Cancer;    Status: Recruiting;   Study ID: NCT01011478

PARP Inhibitor ABT-888 with Carboplatin & Gemcitabline (M10-758) (UW09039)
A Phase 1 Study of ABT-888 (Veliparib) in Combination With Carboplatin (Paraplatin) and Gemcitabline (Gemzar) in Subjects With Advanced Solid Tumors

Investigator: Heidi J. Gray, MD;   Conditions: Advanced Solid Tumors;    Status: Closed;   Study ID: NCT01063816

MDX-1105 for Advanced or Recurrent Cancer (UW08038)
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors

Investigator: Scott S. Tykodi, MD, PhD;   Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer;    Status: Recruiting;   Study ID: NCT00729664

Molecular Markers for Colon Cancer Screening
Validation and Comparison of Biomarkers for the Early Detection of Colorectal Adenocarcinoma

Investigator: William M. Grady, MD;   Conditions: Colon Cancer, Rectal Cancer;    Status: Recruiting;   Study ID: NCT01511653

LY2157299 for Metastatic Cancer and Advanced or Metastatic Pancreatic Cancer
A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)

Investigator: Andrew Coveler, MD;   Conditions: Neoplasms, Neoplasm Metastasis, Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01373164

GS-6624 With FOLFIRI as Second Line Treatment for Colorectal Cancer
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.

Investigator: Andrew Coveler, MD;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01479465

mFOLFOX6 w/Tivozanib or Bevacizumab for Metastatic Colorectal Cancer
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects

Investigator: William P. Harris, MD;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01478594

Dalotuzumab + Irinotecan vs Cetuximab +Irinotecan for Metastatic Rectal Cancers (20111765)
A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination with Irinotecan Versus Cetuximab and Irinotecan for Patients with Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels

Investigator: Edward Lin, MD;   Conditions: Colon Cancer; Rectal Cancer; Solid Tumors;    Status: Recruiting;   Study ID: NCT01609231

MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Phase II, Multicenter, Open-Label, Randomized Study Evaluating The Efficacy And Safety Of Folfiri + Mehd7945a Versus Folfiri + Cetuximab In Second Line In Patients With Kras Wild-Type Metastatic Colorectal Cancer

Investigator: Andrew Coveler, MD;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01652482

Chemotherapy or Chemotherapy + Radiation for Rectal Cancer Patients Undergoing Surgery
A Phase II/III Trial of Neoadjuvant FOLFOX, With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision

Investigator: Alessandro Fichera, MD;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01515787